Sunitinib Malate

For research use only. Not for use in humans.

Licensed by Pfizer Catalog No.S1042

61 publications

Sunitinib Malate Chemical Structure

Molecular Weight(MW): 532.56

Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.

Size Price Stock Quantity  
USD 97 In stock
USD 147 In stock
USD 447 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Sunitinib Malate has been cited by 61 publications

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.
Targets
Kit [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
2 nM 80 nM
In vitro

Sunitinib also potently inhibits Kit and FLT-3. [1] Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 (Flk1) and PDGFRβ with Ki of 9 nM and 8 nM, respectively, displaying >10-fold higher selectivity for VEGFR2 and PDGFR than FGFR-1, EGFR, Cdk2, Met, IGFR-1, Abl, and src. In serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, Sunitinib inhibits VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10 nM and 10 nM, respectively. Sunitinib inhibits VEGF-induced proliferation of serum-starved HUVECs with IC50 of 40 nM, and inhibits PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRβ or PDGFRα with IC50 of 39 nM and 69 nM, respectively. [2] Sunitinib inhibits phosphorylation of wild-type FLT3, FLT3-ITD, and FLT3-Asp835 with IC50 of 250 nM, 50 nM, and 30 nM, respectively. Sunitinib inhibits the proliferation of MV4;11 and OC1-AML5 cells with IC50 of 8 nM and 14 nM, respectively, and induces apoptosis in a dose-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
3T3 MnPRT4lv[XOnIFHzd4F6 MmDSTY5pcWKrdHnvckBw\iCSRFfGMYlv\HWlZXSgRpJlXSCrbnPvdpBwemG2aX;uJJdqfGhiSVO1NEBw\iByLkCwO{DPxE1? NIi3fpgyOjZ2NkCxPS=>
3T3 NVPHR3RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJcohq[mm2aX;uJI9nKFCuYYTlcIV1NWSncnn2[YQh\3Kxd4ToJIZi[3SxcjDpcoR2[2WmIEPUN{Bk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR|UxKG:oIECuNFEh|ryP Ml3XNVI3PDZyMUm=
3T3 M4KwbWZ2dmO2aX;uJGF{e2G7 MY\Jcohq[mm2aX;uJI9nKF[jc3P1cIFzKGWwZH;0bIVtcWGuIHfyc5d1cCCoYXP0c5IhemWlZYD0c5Ihf2m2aDDJR|UxKG:oIECuNFUh|ryP MXqxNlY1PjBzOR?=
3T3 MWXLbY5ie2ViQYPzZZk> MmG0NlAhdWmw Mn73SG1UVw>? MWfD[YxtfWyjcjDpcohq[mm2aX;uJI9nKF[HR1[gbY5lfWOnZDDoeY1idiCNRGKgdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjB{MjFOwG0> NGL6dWUyPjF4MkCwPC=>
NIH3T3 NWC5cmFrU2mwYYPlJGF{e2G7 NVHjTmU4OjBibXnu MUjEUXNQ NXrPW4FvcW6qaXLpeEBpfW2jbjDLSHIhc2mwYYPlJIV5eHKnc4Pl[EB4cXSqIFnDOVAhd2ZiMD6wNVgh|ryP MlvYNVYyPjJyMEi=
A549 NH\x[XRHfW6ldHnvckBCe3OjeR?= MnfWSG1UVw>? NUTyUWRoUW6qaXLpeIlwdiCxZjDjMW1mfCCmZYDlcoRmdnRiSFfGMYlv\HWlZXSgbJVu[W5iQUW0PUBk\WyuIH3p[5JifGmxbjD3bZRpKEmFNUCgc4YhOiEQvF2= MnG0NVg1OzRzNEW=
DU145 M1H4[mZ2dmO2aX;uJGF{e2G7 MX;EUXNQ NWTOV3IyUW6qaXLpeIlwdiCxZjDjMW1mfCCmZYDlcoRmdnRiSFfGMYlv\HWlZXSgbJVu[W5iRGWxOFUh[2WubDDzZ4F1fGW{aX7nJJdqfGhiSVO1NEBw\iBzMDFOwG0> NGLscGkyQDR|NEG0OS=>
KB3-1 MYfDfZRwfG:6aXOgRZN{[Xl? MYK3NkBp M1y3fGROW09? NH7VVoxEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRNWeyLX7l[4F1cX[nIFvCMVMuOSClZXzsd{B4cXSqIFnDOVAhd2ZiMj6zJO69VQ>? M2HMRVE6Ozl5M{Ky
KBV1 NFi0fXZEgXSxdH;4bYMhSXO|YYm= NX[wdnl3PzJiaB?= MYLEUXNQ M1GwdGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHAu\2y7Y3;wdo91\WmwLXX4dJJme3OrbnegT2JXOSClZXzsd{B4cXSqIFnDOVAhd2ZiND6xJO69VQ>? M1PnNVE6Ozl5M{Ky
A375 MUfDfZRwfG:6aXOgRZN{[Xl? MX63NkBp NHTUSVhFVVOR MnTqTWM2OD13LkSg{txO MU[xPVY2PDRyOB?=
RS4-11 NH;LfmpHfW6ldHnvckBCe3OjeR?= NXe5Z2pZOiCq MYHJcohq[mm2aX;uJI9nKE[OVEOgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFk6KM7:TR?= NVnsU3p7OTl4NUS0NFg>
RS4-11 NVP2VVhoTnWwY4Tpc44hSXO|YYm= NUizV4JDOiCq NEPDN4tKdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjB|NDFOwG0> NInRNlAyQTZ3NESwPC=>
Sf9 NX3BTXJNU2mwYYPlJGF{e2G7 MlPDN|AhdWmw NXnYfGRtUW6qaXLpeIlwdiCxZjDHV3QufGGpZ3XkJHZGT0[UIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5zOEWg{txO MX[xPVg2PDB3MR?=
Ba/F3 NWXHfXVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfqXmlWPzJiaB?= MVrJR|UxRTFwMjFOwG0> MVeyNFEyPzByNB?=
BaPTC2 NUXKRW42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e1c|czKGh? NELXcG1KSzVyPUCuNlIh|ryP NXvTdXlbOjBzMUewNFQ>
Sf9 NWrReFRtTnWwY4Tpc44hSXO|YYm= NU\HW4JCOSCq MlnjSG1UVw>? NXe0TmZUUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDIbZMufGGpZ3XkJHJGXCCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEvOyEQvF2= MkK3NlAyOTdyMES=
H4 MVzDfZRwfG:6aXOgRZN{[Xl? M33BZVExKM7:TR?= NGPibYxVd3irY3n0fUBqdiCqdX3hckBJPCClZXzsdy=> M{fJUVIxOzVyOEC2
SF-539 MXvLbY5ie2ViQYPzZZk> NUPrPG9lOzN|IN88US=> MkDtOlAhdWmw MnXCSG1UVw>? M3KxNWlvcGmkaYTpc44hd2ZiUFTHSnJj\XSjIIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNVIvOiEQvF2= MXeyNFQxOzdyMB?=
U251 M{fUcWtqdmG|ZTDBd5NigQ>? M3fhSFM{OyEQvF2= Mn;qOlAhdWmw M1zXb2ROW09? NVjibXBiUW6qaXLpeIlwdiCxZjDWSWdHWjJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCxPE46KM7:TR?= Mk\6NlA1ODN5MEC=
A431 NYnGTGlyU2mwYYPlJGF{e2G7 M1K1c2lvcGmkaYTpc44hd2ZiUFTHSnJj\XSjIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOTJwMjFOwG0> NGTDcGIzODV3OEC3Ni=>
A431 NF7mfYVMcW6jc3WgRZN{[Xl? Ml7hTY5pcWKrdHnvckBw\iCYRVfGVlIh\XiycnXzd4VlKHerdHigTWM2OCCxZjCxPE46KM7:TR?= NGfX[lIzODV3OEC3Ni=>
HepG2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWG3NkBp M1foV2lEPTB;Mz64NUDPxE1? NWL6[GNsOjB3N{C1NlY>
Kasumi-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[yZVczKGh? NYnDSFd3UUN3ME2wMlAyPiEQvF2= NITXNowzODV5MEWyOi=>
RS4-11 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NES0Ro04OiCq NGr0SJZKSzVyPUGg{txO MUeyNFU4ODV{Nh?=
THP1 NFTFNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrWT2ZVPzJiaB?= NV\BcHZuUUN3ME2wMlUh|ryP NG\hVlczODV5MEWyOi=>
Kasumi-1 Mli1SpVv[3Srb36gRZN{[Xl? NFqwe2xKdmirYnn0bY9vKG:oIHOtT4l1KGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODF3IN88US=> MmLMNlA5OzNyM{m=
A549 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13qN|E3KGh? M1;s[2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIO= NVfP[nF[OjF2NUC0OlM>
HL60 NEHpZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqxOkBp MlK4RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\Wyucx?= M{PLUlIyPDVyNE[z
HUVEC NFnmc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3ZZ3VQOTZiaB?= MXLJcohq[mm2aX;uJI9nKF[HR1[tbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDJwN{Wg{txO MoH2NlE1PTB2NkO=
HUVEC M4HTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLMXYJ5OTZiaB?= NX3pXZhWUW6qaXLpeIlwdiCxZjDiSmdHNWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjC0MlA1KM7:TR?= MWCyNVQ2ODR4Mx?=
IM9 NETvTHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH33W2QyPiCq MlH3RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSV25JINmdGy| MmDTNlE1PTB2NkO=
K562 M4fLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLEbGt7OTZiaB?= NUjw[IhXSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gT|U3OiClZXzsdy=> M3nabVIyPDVyNE[z
MDA-MB-231 NILpNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXJXZZlOTZiaB?= M1XhUGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHN? MnXNNlE1PTB2NkO=
H460 NWG2SlkyS3m2b4TvfIlkKEG|c3H5 Mlq4O|IhcA>? MYTJR|UxRTJwNzFOwG0> NXj4T4U3OjF4MkG4PFA>
SMMC7721 NVn2bnp5S3m2b4TvfIlkKEG|c3H5 M2TtVVczKGh? NGL4dnVKSzVyPU[uOFch|ryP Mnn0NlE3OjF6OEC=
WI38 M2rseGN6fG:2b4jpZ{BCe3OjeR?= NUfMcIF1PzJiaB?= NH30[FFKSzVyPUiuOVYh|ryP NFHIXGwzOTZ{MUi4NC=>
HEK293 MYrLbY5ie2ViQYPzZZk> NUXGc2lDOTByIH7N MoDXNUBp MVHkc4V{KG6xdDDpcohq[mm2IG\FS2YucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKG:oIIT5do9{cW6nIEGxO|UhemW|aXT1[UBwdiCYRVfGVlIh\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsdy=> NHvmXoIzOTh6NUK4Oy=>
HUVEC NGrZdVBHfW6ldHnvckBCe3OjeR?= NXTvOnc{OSEQvF2= NXzrZWtsOjRiaB?= Mk\6RY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hXkWJRj3pcoR2[2WmIHPlcIwhdWmpcnH0bY9v NX[0SlZCOjF7NkOzNFU>
HUVEC NIPFUVVHfW6ldHnvckBCe3OjeR?= MlrkNUDPxE1? NYG2T2NHOSCq NInZbnpKdmirYnn0bY9vKG:oIFXST{BxcG:|cHjvdplt[XSrb36gZZQhXGi{MkCyM3R6ejJyNDDpckBXTUeILYP0bY12dGG2ZXSgTHVXTUN? MkDqNlE6PjN|MEW=
HUVEC MWjGeY5kfGmxbjDBd5NigQ>? M17uS|Eh|ryP MWqxJIg> MYDJcohq[mm2aX;uJI9nKGWQT2OgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmei1zMUeyJIlvKF[HR1[td5RqdXWuYYTl[EBJXV[HQx?= M4LuXVIyQTZ|M{C1
HUVEC M{DLUmtqdmG|ZTDBd5NigQ>? MnPBNUDPxE1? MVyxJIg> M1PsVWlvcGmkaYTpc44hd2ZiVlXHSnIzKHCqb4PwbI9zgWyjdHnvckBifCC2eYKtNVE4PSCrbjDWSWdHNXO2aX31cIF1\WRiSGXWSWM> NF23Oo0zOTl4M{OwOS=>
HUVEC Mkn1SpVv[3Srb36gRZN{[Xl? NUDoRnk3OSEQvF2= MoTrNUBp MUTkc4V{KG6xdDDpcohq[mm2IFHLWEBxcG:|cHjvdplt[XSrb36gZZQhW2W{LUS3N{BqdiCYRVfGMZN1cW23bHH0[YQhUFWYRVO= NYT2fWozOjF7NkOzNFU>
HL60 MoXXR5l1d3SxeHnjJGF{e2G7 NXHhOoU2PTBizszN MVO0PEBp MWnEUXNQ NWr4XZNrUUN3ME2xOU42KM7:TR?= NYfQPZY2OjJyMUmxPFg>
K562 NV\2bG9SS3m2b4TvfIlkKEG|c3H5 NXvqb|hpPTBizszN M17lZ|Q5KGh? M{jNcWROW09? NUW5ZWpQUUN3ME2yNU46KM7:TR?= M1Tvc|IzODF7MUi4
PC3 MVHDfZRwfG:6aXOgRZN{[Xl? MnLSOVAh|ryP M{P6TVQ5KGh? MnHKSG1UVw>? M1PlV2lEPTB;MkWuNUDPxE1? M2nLVFIzODF7MUi4
SF-539 MlvDT4lv[XOnIFHzd4F6 MmrmN|M{KM7:TR?= MWC2NEBucW5? NWjDNoVZUW6qaXLpeIlwdiCxZjDQSGdHWmKndHGgeJlzd3OrbnWgb4lv[XOnIHHjeIl3cXS7IHnuJHBFT0ZvQlKtd5RqdXWuYYTl[EBpfW2jbjDTSk02OzliY3XscJMhf2m2aDDJR|UxKG:oIEGyMlIh|ryP NETNNGwzOjJyNEe0NS=>
HAEC M2XId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H3[FExOCEQvF2= M3XjO|czKGh? NIqzdI5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjBSWMh[2WubIOg[ZhxemW|c3nu[{BXTUeIUjD3bZRpKEmFNUCgc4YhOC5zIN88US=> M4HHcVIzPDR2Nke5
HT-29 NXPqfoRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonYNVAxKM7:TR?= MoXSO|IhcA>? M3L2VmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGStNlkh[2WubIOg[ZhxemW|c3nu[{BXTUeIUjD3bZRpKEmFNUCgc4YhOC5|MzFOwG0> NX;HS2FuOjJ2NES2O|k>
MV4-11 NX:4RopZS3m2b4TvfIlkKEG|c3H5 MWG3NkBp M1LwXWlEPTB;MD6wNFMh|ryP NI[xeHEzOjR3MkWxPC=>
HepG2 NFz6[VhEgXSxdH;4bYMhSXO|YYm= NHfGXlM1QCCq Mn;hTWM2OD1zMz6yOEDPxE1? MVOyNlQ5OzZyOB?=
PC9 NUHBd29PS3m2b4TvfIlkKEG|c3H5 NIfGWlQ1QCCq MUfJR|UxRTFyLkm3JO69VQ>? MX2yNlQ5OzZyOB?=
CAKI-1 Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCxNFAh|ryP Mkj0OFghcA>? MXHEUXNQ Ml7oS2k2OD1yLk[zJO69VQ>? Mn;lNlI2PjB4Mke=
EKVX MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDKSmtEOTByIN88US=> NFzxUVQ1QCCq NGHTWFRFVVOR MULHTVUxRTdwOTFOwG0> MWqyNlU3ODZ{Nx?=
MCF7 M1PUVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGqzNmgyODBizszN M4[3e|Q5KGh? Mmn2SG1UVw>? MljsS2k2OT1{IN88US=> NH24ZY4zOjV4ME[yOy=>
MDA-MB-435 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3q4VFExOCEQvF2= NHKzOmk1QCCq MXPEUXNQ NU[2bXpQT0l3Mk2yJO69VQ>? NHPENFgzOjV4ME[yOy=>
OVCAR3 NFXpdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYWxNFAh|ryP NF7Q[lM1QCCq M4j0TmROW09? NYS1eXVIT0l3M{2zMlIh|ryP MmjCNlI2PjB4Mke=
SNB19 M2Djc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITFXnoyODBizszN NU\jdHdWPDhiaB?= MXvEUXNQ MkTZS2k2PD1zMDFOwG0> MoLFNlI2PjB4Mke=
SW620 NIXFfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUexNFAh|ryP MmfwOFghcA>? NGq3R5BFVVOR MVXHTVU2RTFwMzFOwG0> MW[yNlU3ODZ{Nx?=
TK10 MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTrNlgyODBizszN MkjnOFghcA>? MmTaSG1UVw>? Mlj6S2k2Pj14LkOg{txO NVLVdFN5OjJ3NkC2Nlc>
UACC257 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr0RVYyODBizszN MX20PEBp M4O3dGROW09? M{TqfGdKPTd;NDFOwG0> NXL5NZhOOjJ3NkC2Nlc>
HAEC M2nRT2N6fG:2b4jpZ{BCe3OjeR?= NHPmVFIyODBizszN MoO0O|IhcA>? NY\CTIhDTE2VTx?= M{\WRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KF[HR1\SJIV5eHKnc4PpcochUEGHQzD3bZRpKEmFNUCgc4YhOC5zIN88US=> MXSyN|E{OTV2MR?=
HT-29 NWPBW21kS3m2b4TvfIlkKEG|c3H5 M2DYOFExOCEQvF2= MYm3NkBp MY\EUXNQ NYPScIxWS3m2b4TvfIlkcXS7IHHnZYlve3RiVlXHSnIh\XiycnXzd4lv\yCqdX3hckBJXC1{OTDj[YxteyC5aYToJGlEPTBib3[gNE4{OyEQvF2= M2f4TVI{OTNzNUSx
HCT116 M3q1bWZ2dmO2aX;uJGF{e2G7 NEDXbVkzPCCq M{\iTGROW09? MVHBcpRqdWmpcnH0c5J6KGGldHn2bZR6KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[2WubDDtbYdz[XSrb36= NFPON2YzOzF3M{KwNC=>
HUVEC MnSzSpVv[3Srb36gRZN{[Xl? M4nwSlIh|ryP MmraNVghcA>? MlrVSG1UVw>? Mkf1RY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUO|IIXu[IVzKGi7cH;4bYMh[2:wZHn0bY9vKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhfHWkZTDmc5Ju[XSrb36= NGqyRpczOzF3M{KwNC=>
ACHN NFnTfXNEgXSxdH;4bYMhSXO|YYm= M13BbFYh\A>? MoPOTWM2OD1{LkWg{txO MX2yN|M3ODFyNB?=
A498 MWjDfZRwfG:6aXOgRZN{[Xl? M1HwbVExOCEQvF2= M2nYNVczKGh? NHjSNIZFVVOR M4rIbWlEPTB;ND6zJO69VQ>? Mn\iNlM1QDl4Mk[=
HUVEC NFnuU|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlntN{DPxE1? MoO0NlQhcA>? M4HiXGROW09? MnzIRY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCYRVfGMYlv\HWlZXSgeJVj\SCob4LtZZRqd25id3n0bEBGSzVyIH;mJFAvPjR3IN88US=> NXLJfnA1OjN3OEO5NVE>
HUVEC MXHLbY5ie2ViQYPzZZk> NGXyd2gzODBizszN MYnEUXNQ NULXRY1jUW6qaXLpeIlwdiCxZjDWSWdHWjJicHjvd5Bpd3K7bHH0bY9vKGmwIHfyc5d1cCCoYXP0c5Iue3SrbYXsZZRm\CCKVW\FRy=> MoPZNlM2QDN7MUG=
HUVEC NEHpZ|RMcW6jc3WgRZN{[Xl? NFewfJIzODBizszN NGnXcmtFVVOR NUfuWXh1UW6qaXLpeIlwdiCxZjDWSWdHWjFicHjvd5Bpd3K7bHH0bY9vKGmwIHfyc5d1cCCoYXP0c5Iue3SrbYXsZZRm\CCKVW\FRy=> NWDPdVlTOjN3OEO5NVE>
A549 M1HCRWN6fG:2b4jpZ{BCe3OjeR?= MUK3NkBp M{PrcWROW09? M4HNWGlEPTB;Mj60OEDPxE1? M{PqRVI{PjB{NESx
HCT116 MWLDfZRwfG:6aXOgRZN{[Xl? M2DkRVczKGh? MoTiSG1UVw>? NWm3SI1XUUN3ME20MlcyKM7:TR?= M2jVO|I{PjB{NESx
MCF7 NHruNZVEgXSxdH;4bYMhSXO|YYm= MojvO|IhcA>? Mm\GSG1UVw>? MVvJR|UxRTZwMkmg{txO NWLGWHhqOjN4MEK0OFE>
BGC MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX5O|IhcA>? MUfEUXNQ MYLJR|UxRTRwN{ig{txO NIm1ZXMzOzl7OUC0NC=>
BxPC3 M2Pa[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUO3NkBp MlW0SG1UVw>? NELzRWpKSzVyPUOuOlMh|ryP NUKwdopqOjN7OUmwOFA>
HT-29 NFToW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;JOWpHPzJiaB?= M4jSPWROW09? NYPOOXdzUUN3ME2xMlQ4KM7:TR?= NGHmfnkzOzl7OUC0NC=>
T24 NH25WVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnPbnBtPzJiaB?= NEGyOIJFVVOR NUHmRnVzUUN3ME2yMlQ1KM7:TR?= M2qxVFI{QTl7MESw
4T1 NGrIdnBEgXSxdH;4bYMhSXO|YYm= NGHNS244OiCq NYfiTnNpTE2VTx?= MorYTWM2OD1yLkCxOkDPxE1? NF[0OlAzPDh7ME[1Ni=>
MCF7 NGfWZYtEgXSxdH;4bYMhSXO|YYm= MmTaO|IhcA>? NXO1ZWFyTE2VTx?= M4nNUWlEPTB;MD6wNlcyKM7:TR?= M3\6b|I1QDlyNkWy
MCF7 M{jBfWN6fG:2b4jpZ{BCe3OjeR?= NY\lflJUPzJiaB?= Mn7pSG1UVw>? NITPWpRKSzVyPUCuNFI6OyEQvF2= MmS2NlQ5QTB4NUK=
MDA-MB-231 MWTDfZRwfG:6aXOgRZN{[Xl? MYW3NkBp MWLEUXNQ M{XLO2lEPTB;MD6wNlI{KM7:TR?= NXHY[JFDOjR6OUC2OVI>
MDA-MB-435 NY\DfpRRS3m2b4TvfIlkKEG|c3H5 MnTVO|IhcA>? MYLEUXNQ M3HVNGlEPTB;MD6wNFk4KM7:TR?= NIf3RnMzPDh7ME[1Ni=>
MDA-MB-468 MkDlR5l1d3SxeHnjJGF{e2G7 M3TtVVczKGh? NGPicVdFVVOR NFnCdo9KSzVyPUCuNFA3OSEQvF2= NF\qWoYzPDh7ME[1Ni=>
A431 NFjzeWZMcW6jc3WgRZN{[Xl? NHj5NogyOCEQvF2= NUXhfnpqOSCq MlfWSG1UVw>? NV:ySplVUW6qaXLpeIlwdiCxZjDFS2ZTKHerdHigTWM2OCCxZjCwMlE4OjFizszN NInTPGczPDh7ME[1Ni=>
SH-SY5Y NFnUT4ZMcW6jc3WgRZN{[Xl? MX:xNEDPxE1? NIX5[WQyKGh? MW\EUXNQ MXjJcohq[mm2aX;uJI9nKFCGR1\SZoV1[SC5aYToJGlEPTBib3[gNE4xQDNzIN88US=> M{fhflI1QDlyNkWy
U251 M{TBNmtqdmG|ZTDBd5NigQ>? NWHwW4RyOTBizszN NVnySZFyOSCq M37wO2ROW09? MoD0TY5pcWKrdHnvckBw\iCYRVfGVlIhf2m2aDDJR|UxKG:oIECuNFE5QSEQvF2= M3rqdVI1QDlyNkWy
Bel7402 NWjxOoRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7HO|IhcA>? NFPWclFFVVOR MVPJR|UxRTJwNkeg{txO MWSyOFkxPDl4MR?=
HK2 M37sWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYW3NkBp MnLySG1UVw>? MX7JR|UxRTVwOEWg{txO M1Wye|I1QTB2OU[x
LO2 NHHtNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWO0cWVjPzJiaB?= Mn\qSG1UVw>? NYfuVWJPUUN3ME2xPU46OyEQvF2= NHG3WoozPDlyNEm2NS=>
MV4-11 NVjNW4xoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLEOFghcA>? M{DNfGROW09? NFfsWXNKSzVyPUCuNFA{KM7:TR?= MYeyOFkxPDl4MR?=
NCI-H3122 NHLoS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVK3NkBp MXLEUXNQ MWTJR|UxRTBwOEOg{txO MW[yOFkxPDl4MR?=
NCI-H460 Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHifpk4OiCq NFL0clZFVVOR NH25VmFKSzVyPUSuN|Eh|ryP NEDSVo4zPDlyNEm2NS=>
NCI-H526 M1;Fdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:3NkBp MoG3SG1UVw>? NFzPWlRKSzVyPUGuNFEh|ryP NYnXNJlHOjR7MES5OlE>
TT M4Xt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD2ZXY4OiCq Ml;kSG1UVw>? NEDJXW9KSzVyPUCuNFQh|ryP NUnHeXF4OjR7MES5OlE>
EoL-1-cell MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnVb5V2UUN3ME2xMlY1KHCP MUnTRW5ITVJ?
MV-4-11 MlXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYftW3lrUUN3ME2yO|IheE1? NF\5VWJUSU6JRWK=
NOS-1 MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDO[2tLUUN3ME2xOU4{KG6P MkW2V2FPT0WU
CGTH-W-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DuOGlEPTB;M{CuPVQhdk1? NGPyNVBUSU6JRWK=
MONO-MAC-6 NI\vS5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTiXJJKSzVyPUOzMlghdk1? MmT4V2FPT0WU
ALL-PO NUnCdYhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1KyOGlEPTB;N{muPFkhdk1? MYHTRW5ITVJ?
NKM-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X2ZWlEPTB;OUiuOVIhdk1? NXfpNXRwW0GQR1XS
KM12 NFO4No5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfFTWM2OD1|NUCuNVQhdk1? MV\TRW5ITVJ?
TE-15 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\VPWlEPTB;NUC3MlYyKG6P NUTvWpRNW0GQR1XS
697 NWDMT5FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIK5WVFKSzVyPU[xOE4zPSCwTR?= NEDFPFNUSU6JRWK=
MOLT-16 MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorvTWM2OD14M{GuN|Ihdk1? NY[2cYg{W0GQR1XS
GB-1 MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTdzMD6yN{BvVQ>? NX;uNFVQW0GQR1XS
TE-12 M1[2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRThyND61OUBvVQ>? NIfmRXlUSU6JRWK=
ES6 M4TUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDlbYFMUUN3ME25PFEvODZibl2= NYjWSZZTW0GQR1XS
LC-2-ad M1HrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[yVHpKSzVyPUGuNVE1ODdizszN M3LDTnNCVkeHUh?=
BL-70 NUPQ[YFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\XT5lKSzVyPUGuNVE5PDZizszN MXjTRW5ITVJ?
ETK-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjMUo9WUUN3ME2xMlI5PThizszN NWTSTWY1W0GQR1XS
A4-Fuk M{LXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\6NZN5UUN3ME2xMlM1OTRzIN88US=> NXH1To9IW0GQR1XS
OCI-AML2 NVPxT4dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof4TWM2OD1zLkO2PFUyKM7:TR?= MXXTRW5ITVJ?
SIG-M5 NFm2bVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jxdGlEPTB;MT6zO|AxQSEQvF2= MojmV2FPT0WU
NCI-SNU-16 Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLJPGtKSzVyPUGuOFY1QDZizszN MYjTRW5ITVJ?
PSN1 M3PTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vQfGlEPTB;MT61NFY4PiEQvF2= NYXPSWZ2W0GQR1XS
SR NI\uNohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFwNUS1O|Ih|ryP M1rWbXNCVkeHUh?=
A3-KAW MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3GRlNKSzVyPUGuOlI2PDZizszN NX3ZN5k4W0GQR1XS
KS-1 NXmySVRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjMdmZoUUN3ME2xMlY6OjR5IN88US=> M1nWWHNCVkeHUh?=
CTV-1 Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPXOHhKSzVyPUGuO|I4PTFizszN NVnaZmN5W0GQR1XS
LB1047-RCC MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nrfmlEPTB;MT64NVYzPCEQvF2= M1TB[XNCVkeHUh?=
EMG-01 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfSTWM2OD1zLkizOVY{KM7:TR?= Mnm0V2FPT0WU
TE-11 NWjwOFdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrNZYtbUUN3ME2xMlg{QTh3IN88US=> M3TN[XNCVkeHUh?=
CMK MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jUemlEPTB;MT65OVUyPyEQvF2= M1HTWHNCVkeHUh?=
NB1 M2Oxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO4UpRDUUN3ME2xMlk3OTF5IN88US=> Ml;6V2FPT0WU
HAL-01 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;zTWM2OD1{LkC1PVQ3KM7:TR?= M{jZZ3NCVkeHUh?=
DEL NUW3SYtsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrYTWM2OD1{LkC4OFgzKM7:TR?= NF7xUI1USU6JRWK=
RL95-2 NVO4[GxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjtS5BKSzVyPUKuNVEyOzdizszN M1TxNHNCVkeHUh?=
KARPAS-299 NVXmTIZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\PS45KSzVyPUKuNVE{OTNizszN MUjTRW5ITVJ?
EW-16 NHfhUphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S1fWlEPTB;Mj6xN|UxQCEQvF2= NX\iVGxbW0GQR1XS
RS4-11 NF\1R|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli3TWM2OD1{LkG3PVI1KM7:TR?= NH\hSJBUSU6JRWK=
BB30-HNC NWjubpFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLBWW57UUN3ME2yMlIzOzd3IN88US=> NWTkbIk4W0GQR1XS
DOHH-2 MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJwM{O0N|Eh|ryP M{n2d3NCVkeHUh?=
RPMI-8402 MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULUSIo5UUN3ME2yMlM{PjF6IN88US=> Ml;oV2FPT0WU
BV-173 M{e0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJwM{O2OkDPxE1? NIHw[o9USU6JRWK=
TE-10 M2\FOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XPdmlEPTB;Mj6zOFM5PCEQvF2= NUnoOJpZW0GQR1XS
TE-8 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXSepZKSzVyPUKuN|cxOzhizszN M33sS3NCVkeHUh?=
K052 NWLoeJozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfZTlFKSzVyPUKuOFAzODJizszN NW[xcJRiW0GQR1XS
KARPAS-45 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJwNEm0OFYh|ryP MX;TRW5ITVJ?
SK-NEP-1 M1HH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJwNkCyN|ch|ryP NUPneFlMW0GQR1XS
KGN MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{G5SWlEPTB;Mj62NFM{QSEQvF2= M4TYTHNCVkeHUh?=
ML-2 M{XUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfSOmhKSzVyPUKuOlM2OTJizszN MlzkV2FPT0WU
LAMA-84 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXCVJJKSzVyPUKuOlk2PDVizszN MknGV2FPT0WU
LXF-289 Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJwN{K5PFkh|ryP NGjLXm5USU6JRWK=
A101D MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEWwSZNKSzVyPUKuO|g{ODRizszN NXL6W25sW0GQR1XS
KY821 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rsfmlEPTB;Mj63PVc2QCEQvF2= MYTTRW5ITVJ?
ES4 NVvPdFM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrqToZKSzVyPUKuPFA3OjhizszN MXnTRW5ITVJ?
SCC-3 M3Xudmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITvcJFKSzVyPUKuPFI5QTFizszN NX;pRZh7W0GQR1XS
NALM-6 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jGTmlEPTB;Mj65NFQ4OyEQvF2= MnrWV2FPT0WU
BL-41 NV\KZ3o2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjKeVdRUUN3ME2yMlkyOjJ{IN88US=> Mnq5V2FPT0WU
OPM-2 M4Pjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTNwMEW5OVQh|ryP MUHTRW5ITVJ?
SF126 NGX4ZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTNwME[xPVgh|ryP MkjzV2FPT0WU
BE-13 MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3uzWGlEPTB;Mz6yN|EyOSEQvF2= Ml3VV2FPT0WU
SF268 M4jQZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPFTWM2OD1|LkOyPFY6KM7:TR?= MnfhV2FPT0WU
MOLT-4 NWrXSHVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLLTWM2OD1|LkO5PFM5KM7:TR?= MmnPV2FPT0WU
PF-382 M3q5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjkeJdKSzVyPUOuOFQ2PyEQvF2= MnjRV2FPT0WU
HEL MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTjbIxKSzVyPUOuOFgxODVizszN MXLTRW5ITVJ?
RPMI-6666 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjFWot7UUN3ME2zMlU1OTdzIN88US=> M4X5S3NCVkeHUh?=
QIMR-WIL MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDJbGJKSzVyPUOuOlM{QTFizszN M3XkZXNCVkeHUh?=
ATN-1 M4PaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTNwNkexNVQh|ryP Mmn1V2FPT0WU
BB49-HNC MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHxdoM5UUN3ME2zMlcxPTB6IN88US=> NXnoUlRTW0GQR1XS
HCE-4 NVLWcYtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnkfIZiUUN3ME2zMlc5PjR{IN88US=> NVzxNXVjW0GQR1XS
SK-LMS-1 MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGOyZVRKSzVyPUOuPFM{OzhizszN M4DsT3NCVkeHUh?=
MS-1 NWH6TWo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTNwOEO3O|gh|ryP NFrPXmZUSU6JRWK=
JAR NHm2WWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInxbpJKSzVyPUOuPVg5OzJizszN M3jGcHNCVkeHUh?=
KE-37 MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHSTWM2OD12LkC2NVU5KM7:TR?= MmLDV2FPT0WU
LB996-RCC MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTRwMUKxOlgh|ryP MVjTRW5ITVJ?
HH M2LaXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml36TWM2OD12LkKwPVE1KM7:TR?= M{fPWHNCVkeHUh?=
HL-60 MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1f6[GlEPTB;ND6yNVA3PSEQvF2= NVu2fVBmW0GQR1XS
HOP-62 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TWXWlEPTB;ND6zN|UzKM7:TR?= NXnWPJE1W0GQR1XS
NOMO-1 Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGWxelZKSzVyPUSuN|M3QTlizszN NVrY[XdMW0GQR1XS
DU-4475 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHEWXlNUUN3ME20MlM3PzJ7IN88US=> MV\TRW5ITVJ?
LC4-1 M{TvNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXW1T4tuUUN3ME20MlM5ODdizszN MXPTRW5ITVJ?
MC116 M2XJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoCwTWM2OD12LkSzNFgyKM7:TR?= Ml7pV2FPT0WU
SW982 NI\xVVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq5TWM2OD12LkW1N|A4KM7:TR?= MoD0V2FPT0WU
SK-N-DZ M{nKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr3WYxKSzVyPUSuOlcxQTlizszN MonZV2FPT0WU
EW-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TkXmlEPTB;ND62O|kyOSEQvF2= MmTOV2FPT0WU
SU-DHL-1 NWfXWoVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TY[2lEPTB;ND64NFE4PCEQvF2= NWP5ZWNYW0GQR1XS
L-363 NIGyS5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTRwOEC2NlEh|ryP M2DsR3NCVkeHUh?=
OS-RC-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHQV2poUUN3ME20Mlg4OzFizszN M17HW3NCVkeHUh?=
HD-MY-Z MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{SyO2lEPTB;NT6xO|MxOSEQvF2= NWfPSHBPW0GQR1XS
MHH-PREB-1 M3y3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHv4d3NKSzVyPUWuN|I{OTJizszN M1nS[XNCVkeHUh?=
HC-1 NGXrbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjSS|JmUUN3ME21MlQ{OjlzIN88US=> MofNV2FPT0WU
SK-MM-2 M1naW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTVwNEe4NkDPxE1? M4XxOHNCVkeHUh?=
SH-4 NUjFUGF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDvcolKSzVyPUWuOFg{PyEQvF2= MYfTRW5ITVJ?
MHH-CALL-2 M1rmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PZSmlEPTB;NT63OlcyQSEQvF2= MlTOV2FPT0WU
KG-1 NVi3bJpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfBc255UUN3ME22MlAzQDd6IN88US=> M336cnNCVkeHUh?=
J-RT3-T3-5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnuTWM2OD14LkC3PVA6KM7:TR?= NUnHUpRDW0GQR1XS
MMAC-SF MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PUWGlEPTB;Nj6xNFk1QSEQvF2= NYHuPVhpW0GQR1XS
IST-SL2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTZwMUK1NVkh|ryP MmXVV2FPT0WU
SW954 M2X0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDvd4FKSzVyPU[uNlc2OTdizszN MkLBV2FPT0WU
HDLM-2 NGqwXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLhWmNKSzVyPU[uN|IyODlizszN NFrZU|FUSU6JRWK=
ST486 NWn5UHd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYO3d5VKUUN3ME22MlM1PzFizszN M4HwRXNCVkeHUh?=
DG-75 M1jZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M124OGlEPTB;Nj60N|A3QSEQvF2= NV:xWGdLW0GQR1XS
EW-3 M4PIcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\GNmZqUUN3ME22MlQ{OjB5IN88US=> M{DNSnNCVkeHUh?=
8-MG-BA Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfvN4pKUUN3ME22MlUyPTB5IN88US=> M3jR[XNCVkeHUh?=
GT3TKB NVO4Z2w3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\mPWlEPTB;Nj62NFc3OyEQvF2= Ml7pV2FPT0WU
KU812 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITtcJpKSzVyPU[uOlk1OiEQvF2= MkfVV2FPT0WU
CESS NIjiWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTdwMUC0N|gh|ryP MoXtV2FPT0WU
BC-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTdwMkS4NVIh|ryP NIPX[nFUSU6JRWK=
MZ1-PC M4T1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTdwM{CzPFkh|ryP MkfNV2FPT0WU
NCI-H82 M4iwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPxTWM2OD15LkO3PFUh|ryP NULBTGRmW0GQR1XS
NCI-H1355 M3\1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfmS|JKSzVyPUeuOFU5ODRizszN NFjYWJRUSU6JRWK=
RPMI-8226 Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nNdmlEPTB;Nz61NFc{QSEQvF2= MkLJV2FPT0WU
ARH-77 NV7CPIlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moq2TWM2OD15LkWzOVk4KM7:TR?= MoiwV2FPT0WU
MN-60 NF7oWoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT6N5BKSzVyPUeuOVQxQDhizszN M1zr[HNCVkeHUh?=
IMR-5 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLTTWM2OD15MEW0PFc3KM7:TR?= M4LIUXNCVkeHUh?=
KARPAS-422 NYHOTGlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;ifWk{UUN3ME23MlU4OjB4IN88US=> NVLPR5E1W0GQR1XS
CA46 NUS0NplIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\CdohKSzVyPUeuOVgxOTJizszN M1HkfHNCVkeHUh?=
SJSA-1 NInpZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfVTWM2OD15Lk[2NFYyKM7:TR?= NXnDN5dtW0GQR1XS
no-11 NF3S[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDkSVR{UUN3ME23Mlc4PTV5IN88US=> NXjSNmd{W0GQR1XS
IST-SL1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDFbpVqUUN3ME24MlAzPDF5IN88US=> NFLHN4NUSU6JRWK=
NCI-H209 M2\scmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRThwMUG2OVIh|ryP NVT1VGU4W0GQR1XS
TALL-1 NWGwTIJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nQ[WlEPTB;OD6xPFM5PCEQvF2= M3n1ZnNCVkeHUh?=
KMOE-2 NILTbmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7EO21KSzVyPUiuNVk1OiEQvF2= NIH1bFBUSU6JRWK=
HCC1599 NXu4d4R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3QTWM2OD16LkG5PVg4KM7:TR?= NYXaSnIxW0GQR1XS
CI-1 MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fiZ2lEPTB;OD6yNFQyOSEQvF2= NIn6OXZUSU6JRWK=
NCI-H1304 M3zlRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRThwMkC2OlEh|ryP NISweFFUSU6JRWK=
Daudi MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjNTYNKSzVyPUiuNlM2PDZizszN NXz2bo86W0GQR1XS
CPC-N M3iw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRThwMkmxPVkh|ryP MlzGV2FPT0WU
MC-CAR MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3lTWM2OD16LkOzOVgh|ryP MYDTRW5ITVJ?
SW872 M3m1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O0dWlEPTB;OD6zOFc2QCEQvF2= NICxV|JUSU6JRWK=
OVCAR-4 MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2njPWlEPTB;OD61NFM2OSEQvF2= NFf0bIhUSU6JRWK=
OCUB-M NVGxd|hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr4TlUyUUN3ME24MlU3PTB6IN88US=> MknZV2FPT0WU
SK-PN-DW NEDyeGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT5dGNXUUN3ME24MlYxQTh3IN88US=> M3TaXHNCVkeHUh?=
NCCIT MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\kPFdKSzVyPUiuO|E4PDVizszN NFvHeI5USU6JRWK=
NCI-H1648 NYGyPWZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfJXI16UUN3ME25MlE{QDN2IN88US=> M3;pXHNCVkeHUh?=
COR-L279 NV7pVVBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTlwM{mwPUDPxE1? M1;Fd3NCVkeHUh?=
LS-123 M2f4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTlwNkixOlEh|ryP MUTTRW5ITVJ?
LP-1 NWTWSYgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlriTWM2OD17Lke4NFg{KM7:TR?= Mk\BV2FPT0WU
NB13 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonmTWM2OD17Lke5PVk1KM7:TR?= NV3VXlJpW0GQR1XS
ONS-76 MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTlwOEGwNVYh|ryP M2G4RXNCVkeHUh?=
VA-ES-BJ NXG1VFhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL5bpZKSzVyPUmuPVk6OzNizszN MVPTRW5ITVJ?
GR-ST NHnSfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvGfHpKSzVyPUGwMlIzODdizszN NYK3[YpHW0GQR1XS
ES1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTXfmFkUUN3ME2xNE4zQTh2IN88US=> MWTTRW5ITVJ?
NB14 NXHNTW5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPIN|NIUUN3ME2xNE46Ojd5IN88US=> NYnaW3ZDW0GQR1XS
Ramos-2G6-4C10 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnJfopKSzVyPUGxMlI3PSEQvF2= MWPTRW5ITVJ?
RXF393 NV7aWldwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS4VY1wUUN3ME2xNU41QDN2IN88US=> NILYUY9USU6JRWK=
NCI-H2107 MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTFzLkW5PFQh|ryP NIXKemVUSU6JRWK=
K562 NHXqPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDPT4FKSzVyPUGxMlg4ODJizszN MmKyV2FPT0WU
LOUCY M{TwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17lcmlEPTB;MUGuPVg4PSEQvF2= NHnj[IJUSU6JRWK=
TGBC1TKB NVfISIZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTF{LkCwNkDPxE1? NX;oVXJXW0GQR1XS
COLO-320-HSR MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnKenFTUUN3ME2xNk4yPTZ3IN88US=> Mm[2V2FPT0WU
K5 MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTF{LkK5PFUh|ryP NGnJVIpUSU6JRWK=
BC-3 M3fQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF{LkS2OVEh|ryP NIDwbYRUSU6JRWK=
REH NFjGUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTF{Lk[0PVgh|ryP MlT2V2FPT0WU
NEC8 NHm1XYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Lsd2lEPTB;MUKuOlg5PyEQvF2= MV\TRW5ITVJ?
IST-MEL1 M4r1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{C4eGlEPTB;MUKuPFY6PCEQvF2= MmLHV2FPT0WU
NCI-H128 NYrEOYFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jIemlEPTB;MUOuNFczOyEQvF2= MWTTRW5ITVJ?
NCI-H1694 M1XJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzCOm9KSzVyPUGzMlEyPDRizszN NHrsVIpUSU6JRWK=
TGW MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvOTWM2OD1zMz6zNlc3KM7:TR?= MUPTRW5ITVJ?
NCI-SNU-1 M3XGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTF|LkO0OUDPxE1? M4HBW3NCVkeHUh?=
IST-MES1 NWr2e3dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjodZNiUUN3ME2xN{43PzJ7IN88US=> NXXWeFM4W0GQR1XS
CTB-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPTTWM2OD1zMz63Nlk1KM7:TR?= MnHtV2FPT0WU
HUTU-80 MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jMcWlEPTB;MUOuO|U4OyEQvF2= NX\M[JlbW0GQR1XS
LAN-6 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELsNYFKSzVyPUG0MlI1PTdizszN NWO0W4lMW0GQR1XS
KP-N-YS NFzZOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTF2LkK4PVQh|ryP M3zpZ3NCVkeHUh?=
CCRF-CEM M4XocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PGWGlEPTB;MUSuOFE3QSEQvF2= Mn\QV2FPT0WU
NCI-H1770 MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDs[2lKSzVyPUG0MlU{PjlizszN NX7oeFBLW0GQR1XS
MZ2-MEL NVH2XYszT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHZZpFKSzVyPUG1MlIzPTFizszN MYPTRW5ITVJ?
COR-L88 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF4LkCwNVIh|ryP MVnTRW5ITVJ?
LOXIMVI M2\SdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1riNGlEPTB;MU[uNlU3KM7:TR?= MnraV2FPT0WU
KALS-1 NUPxeINNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC0PJFKSzVyPUG2MlU6OzFizszN NH;MPXZUSU6JRWK=
D-283MED NGLx[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e2N2lEPTB;MU[uPFQ5QSEQvF2= MYHTRW5ITVJ?
NCI-H719 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTF4LkmxOlEh|ryP NET0NIpUSU6JRWK=
MLMA NXrsXG9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jUVmlEPTB;MU[uPVkxPyEQvF2= MYfTRW5ITVJ?
EVSA-T Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS2TWM2OD1zNz6wOFg2KM7:TR?= Mn;0V2FPT0WU
SK-N-FI MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrKVGlKSzVyPUG3MlY6OTNizszN MYnTRW5ITVJ?
NTERA-S-cl-D1 M3HWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTF5Lki1O|Ih|ryP NXuyT|dMW0GQR1XS
NCI-H1882 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vWc2lEPTB;MUeuPVg{PCEQvF2= MUfTRW5ITVJ?
A704 MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXsTWM2OD1zNz65PVA1KM7:TR?= Mo\6V2FPT0WU
L-428 MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTQcG9XUUN3ME2xPE4xOTVzIN88US=> MYTTRW5ITVJ?
HCC1187 NFzNPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTp[mNQUUN3ME2xPE4xOTh5IN88US=> NU\TPXJpW0GQR1XS
NCI-H1581 NUPGfYRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPPPGVuUUN3ME2xPE4xQDZ4IN88US=> M1\rXXNCVkeHUh?=
BB65-RCC NFPVU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TTeWlEPTB;MUiuOFE3OiEQvF2= NXzOfnVkW0GQR1XS
EM-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXVTWM2OD1zOD61OlczKM7:TR?= MV7TRW5ITVJ?
Raji M4L4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTpOWhKSzVyPUG5Mlk2PjVizszN M3zGUHNCVkeHUh?=
TE-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\4VGlEPTB;MkCuOFExPCEQvF2= NYnhS5lTW0GQR1XS
SW962 NWD1dlY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJyLkSyPVMh|ryP MmHUV2FPT0WU
MHH-NB-11 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[yNWlEPTB;MkCuOVUzOSEQvF2= NG\qXXFUSU6JRWK=
no-10 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJzLkCyOlQh|ryP M{PCNXNCVkeHUh?=
GDM-1 M{j3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D3bGlEPTB;MkGuPVQyPCEQvF2= NHr0VZdUSU6JRWK=
KMS-12-PE NE\WU3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJ{LkK3OEDPxE1? NFnrVIRUSU6JRWK=
NCI-H510A NFfISI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TR[mlEPTB;MkSuNVI4QCEQvF2= MXfTRW5ITVJ?
ES5 NH;NRnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJ2LkezOFkh|ryP MlTJV2FPT0WU
JiyoyeP-2003 M4Syb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJ4LkK3OFIh|ryP NUjCSJc2W0GQR1XS
NMC-G1 NVfXRYtsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX0TWM2OD1{Nz6xPFIzKM7:TR?= NUDJcmk3W0GQR1XS
NCI-H446 NFjnNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\aWGlEPTB;MkeuOFk1PiEQvF2= M33uPXNCVkeHUh?=
NB7 NVXlfpVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfFXmZbUUN3ME2yO{46OjJ7IN88US=> M1rZ[3NCVkeHUh?=
A388 NXu3fXJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr2PXl7UUN3ME2yPE4xODd2IN88US=> M4LKcnNCVkeHUh?=
JVM-2 NVThOnI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3jTWM2OD1{OD6yPFk5KM7:TR?= MUPTRW5ITVJ?
HT-144 NEPZ[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmSyTWM2OD1{OD62PUDPxE1? MVHTRW5ITVJ?
NCI-H747 M4fsbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;iZmlEPTB;MkiuPVE6PSEQvF2= M3LzZXNCVkeHUh?=
NCI-H1650 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe5eWhKSzVyPUK5MlAyPzZizszN MnPzV2FPT0WU
EB-3 NV;GdINLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzPdmlKSzVyPUK5MlU{ODlizszN M4XWWnNCVkeHUh?=
KLE NVPMTpBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\tOWlEPTB;MkmuOlE6KM7:TR?= MonFV2FPT0WU
TK10 M4fBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\uWGlEPTB;M{CuNVI3KM7:TR?= M3jkbHNCVkeHUh?=
COLO-668 NFvSbVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTNyLke5NkDPxE1? MnjBV2FPT0WU
NCI-H23 NYfiblRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n6fmlEPTB;M{GuNVA3OyEQvF2= NVvG[XRJW0GQR1XS
GOTO MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH3RXFKSzVyPUOxMlYxQDVizszN MmTuV2FPT0WU
MSTO-211H M3\yOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjhTWM2OD1|MT64Olc5KM7:TR?= NEPLNZFUSU6JRWK=
LB831-BLC MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TN[mlEPTB;M{KuN|g1OyEQvF2= NHTRVY5USU6JRWK=
SCH M3jBcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHENWVmUUN3ME2zNk45PDh3IN88US=> MXPTRW5ITVJ?
EHEB Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\VTWM2OD1|ND6xNVk{KM7:TR?= MXrTRW5ITVJ?
U-266 NIG1TYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL6TYNUUUN3ME2zOE4zPzhzIN88US=> NFfZXphUSU6JRWK=
EW-11 NHzSVGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr4c|FVUUN3ME2zOE41PzJ3IN88US=> NHPnenZUSU6JRWK=
TE-9 NI\ie2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjxTlZkUUN3ME2zO{4xPDBzIN88US=> M33MZXNCVkeHUh?=
ES3 NIT4PG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\xTWM2OD1|Nz61NFA1KM7:TR?= MV7TRW5ITVJ?
NCI-H2141 NXXOOWt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjhTWM2OD1|OD6wPFQ{KM7:TR?= NX3ROWp7W0GQR1XS
MPP-89 NXT1eW5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\lUlJQUUN3ME20Nk4xPTh4IN88US=> MmjlV2FPT0WU
SK-MEL-2 M3PmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTR{Lk[0NFUh|ryP M17yXnNCVkeHUh?=
LC-1F Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PwbmlEPTB;NEOuN|Y5OiEQvF2= NILSRY9USU6JRWK=
NH-12 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLk[HdKSzVyPUSzMlk{PTlizszN NFrudJlUSU6JRWK=
RKO NEm5NIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrzTlJKSzVyPUS0MlEzPTJizszN MVrTRW5ITVJ?
KM-H2 NHr3eXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTR2Lkm1O|ch|ryP M4jtR3NCVkeHUh?=
SK-UT-1 NXjtNox6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v3NWlEPTB;NEmuPFgzPSEQvF2= MljaV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-ERK / ERK; 

PubMed: 24759734     


Effect of 72 h treatment with sunitinib on SH-SY5Y, SK N BE(2), SK-N-AS and IMR-32 NB cell lines analyzed by Western blot with pSer473Akt, Akt, pThr202/Thr204 Erk1/2 and Erk1/2 antibodies. β-actin was used as a loading control.

p-GSK3β / GSK3β / MYCN ; 

PubMed: 24759734     


Effect of sunitinib on GSK3β phosphorylation and on MYCN total protein in MYCN amplified NB cell lines.

p-STAT3 / STAT3 / p-Src / Src / p-AKT / AKT / p-ERK / ERK ; 

PubMed: 19244102     


Sunitinib reduced Stat3 and Src activity, with no dramatic reduction of AKT, MAPK and JAK signaling in 786-O cells. Tumor cells were treated with sunitinib at indicated concentrations for 2 h (left panels) or 24 h (right panels). Total cell lysates were prepared and western blots were performed using relevant antibodies to detect total protein levels, with β-actin used as the loading control.

24759734 19244102
Growth inhibition assay
Cell viability; 

PubMed: 24369536     


Isolated effects of sunitinib malate on urinary bladder-cancer cell lines viability, assessed by using the MTT assay. The data shown and bars represent the mean values ± SD (SD: standard deviation). *P < 0.05 versus untreated cells.

24369536
In vivo Consistent with the substantial and selective inhibition of VEGFR2 or PDGFR phosphorylation and signaling in vivo, Sunitinib (20-80 mg/kg/day) exhibits broad and potent dose-dependent anti-tumor activity against a variety of tumor xenograft models including HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435. Sunitinib dosing at 80 mg/kg/day for 21 days leads to complete tumor regression in six of eight mice, without tumor re-growing during a 110-day observation period after the end of treatment. Second round of treatment with Sunitinib remains efficacious against tumors that are not fully regressed during the first round of treatment. Sunitinib treatment results in significant decrease in tumor MVD, with ~40% reduction in SF763T glioma tumors. SU11248 treatment results in a complete inhibition of additional tumor growth of luciferase-expressing PC-3M xenografts, despite no reduction in tumor size. [2] Sunitinib treatment (20 mg/kg/day) dramatically suppresses the growth subcutaneous MV4;11 (FLT3-ITD) xenografts and prolongs survival in the FLT3-ITD bone marrow engraftment model. [3]

Protocol

Kinase Assay:[1]
- Collapse

Biochemical Tyrosine Kinase Assays:

IC50 values for Sunitinib against VEGFR2 (Flk-1) and PDGFRβ are determined using glutathione S-transferasefusion proteins containing the complete cytoplasmic domain of the RTK. Biochemical tyrosine kinase assays to quantitate the trans-phosphorylation activity of VEGFR2 (Flk-1) and PDGFRβ are performed in 96-well microtiter plates precoated (20 μg/well in PBS; incubated overnight at 4 °C) with the peptide substrate poly-Glu,Tyr (4:1). Excess protein binding sites are blocked with the addition of 1-5% (w/v) BSA in PBS. Purified GST-fusion proteins are produced in baculovirus-infected insect cells. GST-VEGFR2 and GST-PDGFRβ are then added to the microtiter wells in 2 × concentration kinase dilution buffer consisting of 100 mM HEPES, 50 mM NaCl, 40 μM NaVO4, and 0.02% (w/v) BSA. The final enzyme concentration for GST-VEGFR2 or GST-PDGFRβ is 50 ng/mL. Twenty-five μL of diluted Sunitinib are subsequently added to each reaction well to produce a range of inhibitor concentrations appropriate for each enzyme. The kinase reaction is initiated by the addition of different concentrations of ATP in a solution of MnCl2 so that the final ATP concentrations spanned the Km for the enzyme, and the final concentration of MnCl2 is 10 mM. The plates are incubated for 5-15 minutes at room temperature before stopping the reaction with the addition of EDTA. The plates are then washed three times with TBST. Rabbit polyclonal antiphosphotyrosine antisera are added to the wells at a 1:10,000 dilution in TBST containing 0.5% (w/v) BSA, 0.025% (w/v) nonfat dry milk, and 100 μM NaVO4 and incubated for 1 hour at 37 °C. The plates are then washed three times with TBST, followed by the addition of goat antirabbit antisera conjugated with horseradish peroxidase (1:10,000 dilution in TBST). The plates are incubated for 1 hour at 37 °C and then washed three times with TBST. The amount of phosphotyrosine in each well is quantitated after the addition of 2,2′-azino-di-[3-ethylbenzthiazoline sulfonate] as substrate.
Cell Research:[3]
- Collapse
  • Cell lines: RS4;11, MV4;11, and OC1-AML5
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24 and 48 hours
  • Method: Cells are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay or trypan blue cell viability assays. Apoptosis is measured 24 hours after Sunitinib addition by Western blotting to detect cleavage of poly (ADP-ribose) polymerase (PARP) or levels of caspase-3.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Female nu/nu mice implanted s.c. with HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435, and male nu/nu mice bearing luciferase-expressing PC-3M tumors
  • Formulation: Formulated as a carboxymethyl cellulose suspension or as a citrate buffered (pH 3.5) solution
  • Dosages: ~80 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 15 mg/mL (28.16 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 532.56
Formula

C22H27FN4O2.C4H6O5

CAS No. 341031-54-7
Storage powder
in solvent
Synonyms N/A
Smiles CCN(CC)CCNC(=O)C1=C(C)[NH]C(=C1C)/C=C/2C(=O)NC3=CC=C(F)C=C23.OC(CC(O)=O)C(O)=O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01391962 Recruiting Drug: Cediranib|Drug: Sunitinib Sarcoma Alveolar Soft Part National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 19 2011 Phase 2
NCT01073644 Terminated Drug: Sunitinib malate Metastatic Renal Cell Carcinoma Pfizer February 2010 --
NCT00912912 Terminated Drug: Sunitinib Malate Genitourinary Disease M.D. Anderson Cancer Center|Pfizer May 2009 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I was wondering that the compound is in its cis or trans form?

  • Answer:

    S1042 Sunitinib Malate is Z form.

  • Question 2:

    What is the difference between Sunitinib Malate(S1042) and Sunitinib(S7781)?

  • Answer:

    S1042 is the Malate salt form of Sunitinib. The biological activities of these two compounds are the same but the solubility of these two compounds in aqueous solvent are different.

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products

Tags: buy Sunitinib Malate | Sunitinib Malate supplier | purchase Sunitinib Malate | Sunitinib Malate cost | Sunitinib Malate manufacturer | order Sunitinib Malate | Sunitinib Malate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID